3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Carcinoma, Hepatocellular
36
Cholangiocarcinoma
11
Carcinoma, Renal Cell
10
Stomach Neoplasms
5
Liver Neoplasms
5
Neoplasms
4
Endometrial Neoplasms
4
Biliary Tract Neoplasms
4
Uterine Cervical Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Vulvar Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Recurrence
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Liver Diseases
2
Kidney Neoplasms
2
Cirrhosis, Familial, with Pulmonary Hypertension
2
Breast Neoplasms
2
Advanced Solid Tumor
2
von Hippel-Lindau Disease
1
Urogenital Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumor, Adult
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Penile Neoplasms
1
Interventions
pembrolizumab
2
lenvatinib
2
aldesleukin
2
Paclitaxel
2
Cisplatin
2
Carboplatin
2
Adoptive Transfer
2
trastuzumab deruxtecan
1
tivozanib
1
liposomal doxorubicin
1
fludarabine
1
dostarlimab
1
belzutifan
1
atezolizumab
1
Vaccines, Synthetic
1
Therapeutic Touch
1
Taxes
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Standard of Care
1
Specimen Handling
1
Radiation
1
Practice Guidelines as Topic
1
Platinum
1
Papillomavirus Vaccines
1
Nivolumab
1
Nelfinavir
1
Imiquimod
1
Hysterectomy
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Vulvar Neoplasms
×
lenvatinib
×
Clear all
NCT05903833
2026-05-11
PIERCE
AGO Research GmbH
Phase 2
Recruiting
42 enrolled
NCT07290894
2026-04-02
MITO VULVA-01
National Cancer Institute, Naples
Phase 2
Recruiting
80 enrolled